

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Insolvency

Ad-hoc: Marinomed Biotech AG files for court restructuring proceedings without self-administration

22-Jul-2026 / 14:43 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by [EQS News](#) - a service of [EQS Group](#).

The issuer is solely responsible for the content of this announcement.

Ad-hoc: Marinomed Biotech AG files for court restructuring proceedings without self-administration

Korneuburg, Austria, July 22nd, 2026 – Marinomed Biotech AG (VSE:MARI) announces the filing of a court restructuring proceeding without self-administration as announced on July 16th.

Marinomed further announces that the existing contract for the provision of liquidity services (market making) with Raiffeisen Bank International has been terminated by the contractual partner with immediate effect. Due to the sudden cessation of market making, there may be a short-term decrease in liquidity for trading Marinomed Biotech AG shares and larger bid-ask spreads. The tradability of the shares on the respective stock exchanges remains fundamentally unaffected. The Management Board is working to agree on a successor market-making mandate promptly and to restore the usual liquidity in the trading of the shares.

Due to the current developments, Marinomed Biotech AG is postponing the publication of its 2026 half-year financial report, which was originally scheduled for September 16, 2026.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: <https://www.marinomed.com>.

For further inquiries contact:

Marinomed Biotech AG

PR: Luca Horinek

IR.: Tobias Meister

T: +43 2262 90300 158

E-Mail: pr@marinomed.com

E-Mail: ir@marinomed.com

Disclaimer

The new shares and subscription rights have not been and will not be registered under foreign securities laws – in particular under the U.S. Securities Act of 1933, as amended ("Securities Act") – with foreign securities authorities and may not be offered or sold, in particular in the United States of America ("US"), without registration or an exemption from the registration requirements under the Securities Act. This communication is not intended for distribution to or within the US and may not be distributed or forwarded to publications with general circulation in the US. This communication constitutes neither an offer to sell nor an invitation to subscribe for or purchase securities in any jurisdiction in which such an offer or such an invitation would be unlawful.

End of Inside Information

22-Jul-2026 CET/CEST News transmitted by [EQS Group](#)

View original content: [EQS News](#)

Language:	English
Company:	Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria
Phone:	+43 2262 90300
E-mail:	office@marinomed.com
Internet:	www.marinomed.com
ISIN:	ATMARINOMED6
WKN:	A2N9MM
Listed:	Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official Market)
LEI Code:	529900GN3B1EN80XF405

EQS News ID: 2370028

End of Announcement

EQS News Service